Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique

PannTheraPi has made significant strides in its clinical and strategic development, highlighted by the submission of a regulatory dossier to initiate a Phase 2a clinical trial for its lead candidate, PTI5803, targeting focal cortical dysplasia (FCD), a rare and severe form of epilepsy. This oral small molecule aims to assess safety, tolerability, pharmacological profile, and initial efficacy signals in both adult and pediatric patients suffering from this pharmacoresistant syndrome. Dr. Gilles Huberfeld, co-founder and neurologist-epileptologist at PannTheraPi, emphasized that this submission marks a pivotal step toward a potential therapeutic solution for patients with limited treatment options.

The regulatory filing is complemented by the recent grant of a European patent protecting the use of PTI5803 in epilepsy, following similar protections already secured in the United States, Canada, and Japan, extending until 2037. This intellectual property fortification not only enhances the commercial viability of PTI5803 but also underscores the therapeutic potential of targeting pannexin 1 (Panx1), a channel implicated in various neurological disorders. The appointment of Sophie Binay as Deputy General Manager and Chief Scientific Officer is expected to accelerate the implementation of clinical strategies and operational structuring, leveraging her extensive experience in R&D project management within the healthtech sector.

The implications of these developments are profound, as they signal a potential shift in the treatment landscape for FCD and related neurological conditions. By advancing PTI5803 into Phase 2a trials, PannTheraPi not only enhances its clinical pipeline but also sets a precedent for future research targeting the pannexin channel, potentially influencing drug development timelines and strategies in the broader field of neurology. This strategic positioning may catalyze further innovations aimed at addressing unmet medical needs in severe neurological and psychiatric disorders.

Source: globenewswire.com